- Home
- BMY
as 07-26-2024 4:00pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 85.8B | IPO Year: | N/A |
| Target Price: | $57.67 | AVG Volume (30 days): | 16.6M |
| Analyst Decision: | Hold | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -3.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.35 - $63.41 | Next Earning Date: | 07-26-2024 |
| Revenue: | $45,534,000,000 | Revenue Growth: | -0.68% |
| Revenue Growth (this year): | 3.42% | Revenue Growth (next year): | -0.08% |
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Investor's Business Daily
5 hours ago
Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win
MT Newswires
6 hours ago
Cantor Fitzgerald Raises Price Target on Bristol-Myers Squibb to $50 From $45
Barrons.com
6 hours ago
These Stocks Are Moving the Most Today: DexCom, 3M, Nvidia, Bristol Myers, Coursera, Biogen, Charter, Deckers, and More
Motley Fool
7 hours ago
Why Bristol Myers Squibb Jumped Nearly 10% on Friday
Motley Fool
8 hours ago
Bristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript
Associated Press Finance
8 hours ago
Newell Brands, 3M rise; Saia, DexCom fall, Friday, 7/26/2024
MT Newswires
9 hours ago
Top Midday Stories: Fed's Preferred Inflation Reading Up in June; 3M's Adjusted Earnings Gain; DexCom Cuts 2024 Revenue Guidance; Bristol-Myers Squibb's Higher Results; WesBanco, Premier Financial to Merge
The Wall Street Journal
9 hours ago
Stocks to Watch Friday: DexCom, 3M, Coinbase, Charter
Compare BMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.